Experts Released Alopecia Areata Treatment Guidelines
New standardized recommendations for severe alopecia areata establish JAK inhibitors as a primary long-term therapy.
Updated on Sept. 22, 2026 in Allergies
Live Poll
Do you believe standardized medical treatment guidelines improve the quality of care for patients?
The National Alopecia Areata Foundation and the American Hair Research Society have issued the first standardized U.S. treatment recommendations for adults living with severe alopecia areata. This new guidance, published in JAMA Dermatology, aims to eliminate inconsistent care by establishing oral JAK inhibitors as the primary long-term treatment.
Why it matters
The guidance addresses a significant lack of uniformity in clinical practice that previously resulted in delayed patient access to effective therapies. By providing a clear roadmap for care, the recommendations seek to improve outcomes for the approximately 300,000 U.S. adults suffering from the condition.
A panel of 30 specialists reviewed clinical data on 29 different treatments to establish these guidelines for the 300,000 U.S. adults with severe disease. The consensus process evaluates interventions to improve upon the current 2.5% lifetime prevalence of alopecia areata.
The players
National Alopecia Areata Foundation
This non-profit organization focuses on supporting those affected by alopecia areata through research funding and community advocacy.
American Hair Research Society
This professional medical organization is dedicated to promoting clinical and scientific study regarding hair and scalp disorders.
The details
The steering group developed these recommendations through a rigorous multi-round survey process that analyzed existing data on 29 distinct therapeutic options. Beyond medication, the protocol mandates the integration of mental health screenings and formal patient advocacy referrals into the overall management plan.
Timeline
September 22, 2026: The standardized treatment recommendations were officially issued and published.
The Big Picture
This story follows the standard established by the JAMA Dermatology consensus guidance process for determining best-practice treatment protocols. The initiative marks a shift toward unified care models in dermatology, replacing fragmented approaches with a centralized, evidence-based strategy.
Patients may now experience more consistent care pathways and faster access to oral JAK inhibitors as their physicians adopt these national standards. The incorporation of mandatory mental health screenings ensures that the psychological toll of the condition is addressed alongside physical hair regrowth.
The takeaway
Patients should discuss these new standards with their dermatologists to determine if oral JAK inhibitors are an appropriate long-term option for their specific medical history. Utilizing resources from advocacy organizations can also help patients find the necessary support systems integrated into this new management model.
What happens next
The guidance is designed as a living resource, with plans for the steering group to conduct ongoing updates as new clinical evidence and treatment data become available.
Further reading
Learn more about the latest clinical standards in our Allergies section.
More information
For more information, visit the NAAF official treatment recommendations resource.
Live Poll
Do you believe standardized medical treatment guidelines improve the quality of care for patients?
